Oncology Conference update

How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Dr Joshua Sabari

Publication Date

Sep 2026

Summary and next episodes

Downloadable resources

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Thoracic oncologist Dr Joshua Sabari joined us from WCLC 2026 in Seoul to report on the latest data and share his expert perspective on the most recent advances in HER2-mutant non-small cell lung cancer (NSCLC).

Dr Sabari shares insights on the following studies:

DESTINY-Lung04: First-line trastuzumab deruxtecan in patients with metastatic HER2-mutant NSCLC (Primary Results)
Rotow J, et al. Abstract PL03.08, WCLC 2026
SOHO-01: Molecular landscape of acquired resistance to sevabertinib in HER2-mutant NSCLC (Exploratory Biomarker Analysis)
Le X, et al. Abstract MO12.04, WCLC 2026
Beamion LUNG-1: Acquired resistance to zongertinib treatment in patients with HER2-mutant NSCLC (Phase 1b Study)
Planchard D, et al. Abstract MO12.05, WCLC 2026

Clinical Takeaways

DESTINY-Lung04: First-line trastuzumab deruxtecan significantly improved PFS versus standard chemo-immunotherapy in advanced HER2-mutant NSCLC, supporting a potential shift towards HER2-directed treatment in the first-line setting
SOHO-01: Exploratory biomarker analysis provides early insights into potential mechanisms of acquired resistance to sevabertinib, identifying secondary HER2 T862A as the most frequent putative genomic resistance alteration
Beamion Lung-1: Exploratory biomarker analysis suggests resistance to zongertinib is molecularly heterogeneous, with diverse genomic alterations converging on common biological pathways

Want to know more about the data? View and download the accompanying slides on the 'Slides' tab for a deeper dive.

See more lung cancer data from recent conferences: Catch up on Highlights from ASCO 2026 and Oncogene-addicted NSCLC highlights from ELCC 2026 on the right of this page, or scroll up to 'Summary and next episodes' if you're on mobile.

Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC

Dr Sabari grew up in Brooklyn, New York and was interested in science and problem solving from an early age. As a child, he loved taking things apart so he could figure out how they worked. During his undergraduate education, he majored in philosophy where he studied ethics and shared decision making. It was this same passion, partnered with his compassion for others, that inspired him to attend medical school and ultimately choose the specialty of oncology.

At NYU Langone’s Perlmutter Cancer Center, he specialises in caring for people who have lung cancers, including non-small cell lung cancer and small cell lung cancer. Dr Sabari understands that a cancer diagnosis is frightening, and navigating treatment can be overwhelming. Dr Sabari believes that every person should be treated as an individual and receive personalised treatment and care. His goal is to help guide patients and their families through treatment, so they feel comfortable, supported, and confident in their care.

Dr Sabari works closely with a team of cancer specialists to deliver advanced treatments with a compassionate and patient-centred focus. Together, they strive to fight cancer and minimise its physical symptoms, so everyone under their care can spend their lives doing what matters most to them.

Dr Sabari’s research focuses on developing new treatments for people with lung cancers. His goal is to develop biomarker-driven clinical trials that offer patients unprecedented access to novel therapies and personalised treatments. Dr Sabari aims to better understand why people develop cancer and wishes to create innovative ways to harness the body’s immune system to fight cancer.

Dr Joshua Sabari has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, EMD Serono, Genentech, Janssen, Jazz, Loxo Lilly, Mirati/BMS, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda

Download Slides - PDF

Download Slides - PPTX

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Watch the video using the tab above to get Dr Sabari’s insights on the following studies:

DESTINY-Lung04: First-line trastuzumab deruxtecan in patients with metastatic HER2-mutant NSCLC (Primary Results)
Rotow J, et al. Abstract PL03.08, WCLC 2026
SOHO-01: Molecular landscape of acquired resistance to sevabertinib in HER2-mutant NSCLC (Exploratory Biomarker Analysis)
Le X, et al. Abstract MO12.04, WCLC 2026
Beamion LUNG-1: Acquired resistance to zongertinib treatment in patients with HER2-mutant NSCLC (Phase 1b Study)
Planchard D, et al. Abstract MO12.05, WCLC 2026

Clinical Takeaways

DESTINY-Lung04: First-line trastuzumab deruxtecan significantly improved PFS versus standard chemo-immunotherapy in advanced HER2-mutant NSCLC, supporting a potential shift towards HER2-directed treatment in the first-line setting
SOHO-01: Exploratory biomarker analysis provides early insights into potential mechanisms of acquired resistance to sevabertinib, identifying secondary HER2 T862A as the most frequent putative genomic resistance alteration
Beamion Lung-1: Exploratory biomarker analysis suggests resistance to zongertinib is molecularly heterogeneous, with diverse genomic alterations converging on common biological pathways

Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC

Download Slides - PDF

Download Slides - PPTX

Programme summary

Duration 5 MIN
Downloadable resources Yes
Download Slides - PDF
Download Slides - PPTX
Language(s)

Watch the video now

Other episodes of this series

Highlights from ASCO 2026

Expert insights on the latest data